Quick Answer
RetinalGenix Technologies Inc. reported Diluted EPS of $0.24 per share (loss) for fiscal year 2024.
RetinalGenix Technologies Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$0.24 | -100.0% |
| 2023 | -$0.12 | +52.0% |
| 2022 | -$0.25 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.03 | +25.0% | +11.8% |
| June 30, 2025 | -$0.03 | +15.0% | -13.3% |
| March 31, 2025 | -$0.03 | +75.0% | +25.0% |
| September 30, 2024 | -$0.04 | +0.0% | +0.0% |
| June 30, 2024 | -$0.04 | -100.0% | +66.7% |
| March 31, 2024 | -$0.12 | -300.0% | -200.0% |
| September 30, 2023 | -$0.04 | +73.3% | -100.0% |
| June 30, 2023 | -$0.02 | +0.0% | +33.3% |
- RetinalGenix Technologies Inc. showed a decrease of -100.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2024 period, RetinalGenix Technologies Inc.’s diluted eps has grown by 4.0% (from $0.25 per share (loss) to $0.24 per share (loss)).
- The most recent figure is from RetinalGenix Technologies Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: